ArticleActa neurologica Belgica2026
Subcortical shape alterations in spinocerebellar ataxia type 2: a longitudinal MRI-based analysis.
Article in Acta neurologica Belgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeSpinocerebellar ataxia type 2 (SCA2) is a progressive autosomal dominant neurodegenerative disorder characterized by cerebellar and extracerebellar involvement. Although volumetric MRI studies have demonstrated cerebellar and supratentorial gray matter changes, region-specific shape alterations of subcortical structures remain insufficiently characterized. This study aimed to investigate cross-sectional and longitudinal subcortical gray matter shape changes in genetically confirmed SCA2 using a vertex-based morphometric approach.
methodsStructural T1-weighted MRI data from nine patients with genetically confirmed SCA2 and sixteen age- and sex-matched healthy controls were obtained from the publicly available OpenNeuro repository. All participants underwent baseline imaging and follow-up scans after a mean interval of approximately 3.5 years. Subcortical structures were segmented using the FSL-FIRST framework. Vertex-wise shape analyses were performed using permutation-based statistics adjusted for age, sex, and total brain volume. eTIV-normalized subcortical volumetric analyses were also performed to assess cross-sectional and longitudinal volume differences between groups.
resultsCompared with healthy controls, patients with SCA2 demonstrated localized outward shape deformations in the right hippocampus, left caudate nucleus, and left putamen (p < 0.05, FWE-corrected). Longitudinal analyses revealed more pronounced deformation patterns involving the left caudate nucleus, left pallidum, and left putamen in the SCA2 group compared with temporal changes observed in controls (p < 0.05, FWE-corrected). eTIV-normalized volumetric analyses demonstrated significantly reduced brainstem and bilateral thalamic volumes in patients with SCA2 at both baseline and follow-up assessments. In longitudinal analyses, significantly greater volume loss was observed in the left pallidum and bilateral hippocampi in the SCA2 group.
conclusionsVertex-based shape analysis demonstrated progressive and region-specific subcortical abnormalities in SCA2 and revealed morphological alterations that were only partially captured by conventional volumetric measurements. The partial concordance between shape-based and volumetric findings, particularly in the left pallidum, supports the biological relevance of the observed structural changes. Together, shape and volumetric analyses provide complementary information and may improve the characterization of subcortical involvement and longitudinal disease-related changes in SCA2.
Indexed as
Identifiers
42449040What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.